Oncomine Dx Express Test en Oncomine Reporter Dx-informatica combineren met Ion Torrent Genexus Dx-systeem om klinisch relevante biomarker resultaten te leveren in slechts één dag
CARLSBAD, Californië–(BUSINESS WIRE)– Next-generation sequencing (NGS) wordt snel het voorkeursplatform voor moleculaire profilering van tumoren vanwege het vermogen om gelijktijdig over meerdere biomarkers te rapporteren. Lange doorlooptijden kunnen echter de klinische bruikbaarheid van deze resultaten beperken. Om aan de behoefte aan snelle genomische inzichten te voldoen, heeft Thermo Fisher Scientific vandaag de CE-IVD (IVDD) Oncomine Dx Express Test en Oncomine Reporter Dx gelanceerd voor gebruik in klinische laboratoria.
Thermo Fisher Scientific Launches CE-IVD (IVDD) Next-Generation Sequencing Test and Analysis Software to Expand Access to Precision Oncology Biomarker Testing
Oncomine Dx Express Test and Oncomine Reporter Dx informatics combine with Ion Torrent Genexus Dx System to deliver clinically relevant biomarker results in as little as one day
CARLSBAD, Calif.–(BUSINESS WIRE)– Next-generation sequencing (NGS) is quickly becoming the platform of choice for tumor molecular profiling due to its ability to simultaneously report on multiple biomarkers. However, lengthy turnaround times can limit the clinical utility of these results. To meet the need for rapid genomic insights, Thermo Fisher Scientific today launched the CE-IVD (IVDD) Oncomine Dx Express Test and Oncomine Reporter Dx for use in clinical labs.
Using targeted NGS technology, the Oncomine Dx Express Test delivers clinically relevant tumor mutation profiling in as little as 24 hours to aid healthcare professionals, in accordance with professional guidelines, in therapy management of cancer patients. The qualitative in vitro diagnostic (IVD) test detects deletions, insertions, substitutions and copy number gain present in 42 genes and fusions or splicing variants in 18 genes from DNA and RNA in FFPE tumor tissue samples of solid malignant neoplasms. This assay also detects deletions, insertions, substitutions in 42 genes and fusions or splicing variants in seven genes from cfTNA extracted from plasma samples of non-small cell lung cancer (NSCLC). The assay requires minimal sample input, maximizing sample success rates.
The Oncomine Reporter Dx software ensures healthcare providers can quickly assess the genomic test results. The software matches the variant data to relevant evidence including approved therapies, guidelines, clinical trials and peer reviewed literature in a user-friendly and customizable report.
“Genomic profiling in precision oncology is transforming cancer care, but true clinical utility hinges on timely, actionable results,” said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “By delivering an IVD NGS solution that provides rapid results with minimal training and hands-on time, we’re working to make these insights available in any lab or hospital to help connect patients to precision oncology treatments.”
The new NGS assay and genomic reporting software, along with the recently launched Ion Torrent Genexus Dx Integrated Sequencer, offer an automated end-to-end CE-IVD workflow. Operated from a single software interface, the overall process includes less than 20 minutes of hands-on time, delivering results with unprecedented rapid turnaround time. The workflow enables any lab to bring the power of genomic testing in-house, improves access to patients and advances precision oncology for those who stand to benefit most.
For more information on the Oncomine Dx Express Test and the Oncomine Reporter Dx, please visit thermofisher.com/oncomine-dxtarget.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.